Although there have been no randomized controlled studies on anti-TNF drugs in patients with SSc or SSc-ILD, observational studies from the early 2000s suggested that anti-TNF drugs such as infliximab and etanercept might improve inflammatory arthritis and disability in patients with SSc (35, 36). This evidence concerns the gene TNF and systemic sclerosis.